Q&A With the Experts: What about reserve samples for pharmaceutical product and materials?

Overview

Reserve samples are retained portions of products or materials used to verify quality and support investigations after distribution. FDA regulations such as 21 CFR 211.170 and 21 CFR 111.83(b)(4) govern their preservation, retention, and handling. These requirements ensure manufacturers can conduct effective investigations into product quality issues, stability concerns, or complaints.

1. Drug Products

Reference: 21 CFR 211.170

Products Requiring Reserve Samples

• A reserve sample from each lot or batch of the finished drug product.
• A reserve sample of each active ingredient.

Retention Period

• Drug products: retain for 1 year after expiration.
• Radioactive drugs:
  • If the dating period ≤ 30 days → 3 months after expiration.
  • If the dating period > 30 days → 6 months after expiration.
• OTC drugs without expiration date: retain for 3 years after distribution.
• Active ingredients: retain for 1 year after the expiration of the last lot of product containing the ingredient.

2. Bioavailability (BA) and Bioequivalence (BE) Samples

Reference: FDA Guidance, Handling and Retention of BA and BE Testing Samples

Materials Requiring Reserve Samples

• Reserve samples of any test article and reference standard used in in vivo or in vitro BE studies.

Retention Period

• Generally 1 year after product expiration, consistent with drug product requirements.
• Emphasis on sample integrity, proper quantity, and random selection to ensure study validity.

3. Dietary Supplements

Reference: 21 CFR 111.83(b)(4)

Products Requiring Reserve Samples

• Reserve samples of each lot of packaged and labeled supplement distributed.

Retention Period

• If shelf-life dating is used → 1 year past the shelf-life date.
• If no dating is used → 2 years after distribution of the last associated batch.

4. Common FDA Deficiencies (21 CFR 211.170)

1. Failure to retain representative samples.
   Firms omitted reserve samples for each lot of API or finished drug product, limiting the ability to investigate complaints or stability issues.
2. Insufficient quantity.
   Samples did not contain twice the amount required for all specified tests (except sterility or pyrogenicity).
3. Improper storage conditions.
   Samples were not stored according to labeled requirements, such as temperature control.
4. Inappropriate container-closure system.
   Samples were not kept in the same or equivalent packaging as the marketed product, affecting representativeness.
5. Inadequate segregation and access control.
   Samples were stored in areas without appropriate separation or access restrictions, increasing the risk of mix-ups or tampering.

Key Takeaway

FDA inspection findings emphasize traceability, integrity, and representativeness of reserve samples. Companies should maintain samples of sufficient quantity, stored under the proper conditions, and restrict access to authorized personnel to enable reliable investigations of quality or stability concerns.